Leads Biolabs Advances Cancer Treatment with Opamtistomig in Clinical Trials Leads Biolabs has successfully dosed the first patient with Opamtistomig (LBL-024) in a pivotal study for esophageal cancer treatment, aiming for superior survival outcomes.

Leads Biolabs Advances Cancer Treatment with Opamtistomig in Clinical Trials #China #Leads_Biolabs #Nanjing #Opamtistomig #ESCC

Leads Biolabs Unveils Promising Clinical Data for LBL-034 at 2025 ASH Annual Meeting At the 2025 ASH Annual Meeting, Leads Biolabs presented groundbreaking results on LBL-034, a bispecific antibody for relapsed myeloma patients, showcasing its effectiveness and safety.

Leads Biolabs Unveils Promising Clinical Data for LBL-034 at 2025 ASH Annual Meeting #USA #Leads_Biolabs #Orlando #Multiple_Myeloma #LBL-034

Leads Biolabs Announces FDA Approval for LBL-047, a Novel Autoimmune Therapy Leads Biolabs has received FDA approval for LBL-047, an innovative bispecific fusion protein targeting autoimmune diseases, marking a significant milestone in treatment development.

Leads Biolabs Announces FDA Approval for LBL-047, a Novel Autoimmune Therapy #China #Leads_Biolabs #Nanjing #Autoimmune_Disease #LBL-047

Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial Leads Biolabs announces the successful dosing of the first patient in the Phase Ⅱ trial of LBL-034, a bispecific T-cell engager aiming to target GPRC5D in cancer.

Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial #Leads_Biolabs #GPRC5D #LBL-034

Leads Biolabs Achieves Milestone in Clinical Trial for Opamtistomig Against Neuroendocrine Carcinoma Leads Biolabs has successfully completed patient enrollment in a pivotal trial for Opamtistomig, an innovative treatment for extrapulmonary neuroendocrine carcinoma.

Leads Biolabs Achieves Milestone in Clinical Trial for Opamtistomig Against Neuroendocrine Carcinoma #China #Leads_Biolabs #Nanjing #Clinical_Trials #Opamtistomig

Leads Biolabs Achieves Successful HKEX Listing with $189 Million IPO Nanjing Leads Biolabs Co., Ltd. made its debut on the Hong Kong Stock Exchange, securing $189 million through its IPO to enhance clinical trials and technologies.

Leads Biolabs Achieves Successful HKEX Listing with $189 Million IPO #China #Leads_Biolabs #Nanjing #biotechnology #HKEX

Leads Biolabs Unveils Promising LBL-024 Results at 2025 ASCO Meeting Leads Biolabs presented groundbreaking data on LBL-024 for treating advanced neuroendocrine carcinoma, showcasing impressive results at the 2025 ASCO.

Leads Biolabs Unveils Promising LBL-024 Results at 2025 ASCO Meeting #China #Leads_Biolabs #LBL-024 #Nanjing #ASCO_2025

Leads Biolabs' LBL-024 Achieves FDA Orphan Drug Designation for Rare Cancer Treatment Leads Biolabs has received FDA Orphan Drug Designation for LBL-024, aimed at treating advanced neuroendocrine cancer, highlighting its potential therapeutic impact.

Leads Biolabs' LBL-024 Achieves FDA Orphan Drug Designation for Rare Cancer Treatment #USA #Leads_Biolabs #LBL-024 #Neuroendocrine_Cancer #Nanjing